No Data
No Data
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies fo
Board Observer of Taysha Gene Therapies Picks Up 5.7% More Stock
Those following along with Taysha Gene Therapies, Inc. (NASDAQ:TSHA) will no doubt be intrigued by the recent purchase of shares by Paul Manning, Board Observer of the company, who spent a stonking US
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing
Paul B Manning, 10% Owner, on June 27, 2024, executed a purchase for 1,333,333 shares in Taysha Gene Therapies (TSHA) for $2,999,999. Following the Form 4 filing with the SEC, Manning has control over
Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $7
Piper Sandler analyst Christopher Raymond maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and adjusts the target price from $9 to $7.According to TipRanks data, the analyst has a success